FOXO4-DRI

What is FOXO4-DRI?

FOXO4-DRI is a synthetic peptide designed to kill senescent cells, the damaged cells that stop dividing but do not die. Drugs with this aim are called senolytics. FOXO4-DRI was created by Peter de Keizer's research group in the Netherlands and became widely known after a 2017 mouse study published in the journal Cell. It is sometimes sold under the name Proxofim.

Reviews of aging research have listed FOXO4-DRI among the more promising experimental anti-aging agents.² That attention, together with striking before-and-after photos of aged mice, created demand for it online.

FOXO4-DRI is not approved anywhere and has no published human data. It is sold as a research chemical for longevity, and its legal status is covered in the box on this page.

How FOXO4-DRI works

As we age, senescent cells build up in tissues. They release a mix of inflammatory signals and growth factors that disturb nearby healthy cells and reduce the body's ability to repair itself.¹ Many senescent cells survive because of a protein called FOXO4, which holds another protein, p53, in a way that stops it from triggering cell death. FOXO4-DRI acts as a decoy. It gets between FOXO4 and p53, freeing p53 to start the cell's self-destruct program.³ Healthy cells have little FOXO4 bound to p53, so in theory they are left alone.

The DRI in the name stands for D-retro-inverso. The peptide is built from D-amino acids, the mirror images of the natural L-forms, arranged in reverse order. This design mimics the shape of the natural FOXO4 segment that binds p53, while making the peptide resistant to the enzymes that normally break proteins down. Once released, p53 moves toward the mitochondria and activates the internal pathway of programmed cell death.

What the research shows on FOXO4-DRI

All of the evidence comes from cells and animals. The key 2017 study reported that FOXO4-DRI cleared senescent cells in fast-aging and naturally old mice and improved fitness, fur density and kidney function.

Broader reviews of senolytics describe the same pattern. A 2018 review noted that compounds that remove senescent cells restored tissue health in old mice, improved kidney function and extended healthy lifespan in animals. The authors proposed testing them to improve kidneys from older donors for transplant.¹

A 2026 review focused on the brain. It summarized animal studies in which FOXO4-DRI reduced senescent cells, restored blood flow and blood-brain barrier integrity, reversed shrinkage of the hippocampus and improved cognition in aged animals, and cleared amyloid and tau in Alzheimer's and tauopathy models.³ The human evidence that review cites comes from other senolytic approaches, such as high-dose fisetin, not from FOXO4-DRI.³

The limits are clear. No human trial of FOXO4-DRI has been published. Mouse aging differs from human aging, the animal studies are small and come from a limited number of labs, and the doses used in mice do not translate simply to people. Narrative reviews tend to collect positive results, so the full picture may be less favorable.

There is also a gap between clearing senescent cells and slowing human aging. Senescence is only one of several proposed drivers of aging. It is not known whether removing these cells in middle-aged or older people improves health, how often treatment would be needed or whether the benefits would outweigh the harms.

Studied for: Senolytic research, Longevity research.

FOXO4-DRI reference data

FOXO4-DRI dosage in published research

Open this in the dosage calculator ↗

How FOXO4-DRI is used in practice

FOXO4-DRI is not prescribed by clinicians and is not available from compounding pharmacies. It is sold by research-chemical vendors, often at high prices, as freeze-dried powder for injection. Users typically follow intermittent protocols of a few doses per cycle, loosely based on mouse studies. The intermittent approach reflects the idea behind senolytics in general: senescent cells build up slowly, so a short course might clear them for a long time. The right interval in people, if there is one, is unknown.

Product quality is a major issue. FOXO4-DRI is a long peptide made from D-amino acids, which is expensive and technically demanding to produce. Cheap products are unlikely to be the correctly made full-length peptide, and impurities from incomplete synthesis are common in this kind of product. No regulator checks what these vials contain.

Some people try to verify senolytic effects with blood tests or biological age clocks. None of these is validated for judging whether a senolytic is working in an individual.

FOXO4-DRI risks and side effects

Human side effects are unknown. Users report injection-site reactions and fatigue, but there is no systematic safety data.

There are reasons for caution. Senescent cells are not only harmful. They help with wound healing and tissue repair and act as a barrier against cancer by stopping damaged cells from dividing. Removing them, or activating p53 more widely, could have effects that mouse studies were not designed to detect. A peptide made of unnatural D-amino acids may also trigger immune reactions with repeated use. Killing many cells at once could also, in principle, release cell contents and inflammatory signals. Whether that matters at the doses people use is unknown.

People who are pregnant, have active cancer or have a weakened immune system should avoid it. Interactions with other drugs, especially cancer treatments that also act through p53, are unknown.

Reported side effects

Alternatives to FOXO4-DRI

No senolytic drug is approved. Other senolytics, such as the combination of dasatinib and quercetin, and fisetin, are being tested in early human trials, but they remain experimental and carry their own risks.³ Taking part in a registered trial is the safest way to try one. Store-bought fisetin and quercetin supplements are often marketed as senolytics, but they have not been shown to clear senescent cells in people at typical supplement doses.

For healthy aging today, the best evidence supports regular exercise, not smoking, managing blood pressure, cholesterol and blood sugar, keeping a healthy weight, getting enough sleep and following recommended screening. For kidney disease, approved treatments such as ACE inhibitors, angiotensin receptor blockers and SGLT2 inhibitors slow decline.

Questions for a clinician

• What evidence applies to my situation, and at what level?
• What established alternatives should I consider first?
• What monitoring would be necessary, and how often?
• Can this be prescribed at all where I live, or only sold for research?